Angioplasty Balloons Market Size, Share and Trends 2024 to 2034

Angioplasty Balloons Market Size and Forecast 2024 to 2034

The global angioplasty balloons market size is projected to be worth around USD 3.86 billion by 2034 from USD 2.63 billion in 2024, at a CAGR of 3.92% from 2024 to 2034. The North America angioplasty balloons market size reached USD 1.04 billion in 2023. The increasing prevalence of cardiovascular diseases across the world driving the growth of the market.

Angioplasty Balloons Market Key Takeaways

• North America dominated the angioplasty balloons market with the largest market share of 41% in 2023.
• Asia Pacific is estimated to grow at a CAGR of 4.71% during the forecast period.
• By type, the normal balloons segment has contributed the largest market share of 55% in 2023.
• By type, the scoring balloons segment is projected to expand at a CAGR of 5.63% during the forecast period.
• By application, the coronary segment has generated the biggest market share of 55% in 2023.
• By application, the peripheral vascular diseases segment is estimated to grow at a CAGR of 4.51% during the forecast period.
• By end-use, the Ambulatory Surgical Centres (ASCs) segment has held a major market share of 53% in 2023.
• By end-use, the hospitals segment held the second-largest share of the market in 2023.

U.S. Angioplasty Balloons Market Size and Growth 2024 to 2034

The U.S. angioplasty balloons market size was exhibited at USD 780 million in 2023 and is projected to be worth around USD 1,210 million by 2034, poised to grow at a CAGR of 4.07% from 2024 to 2034.

North America has contributed the highest market share of 41% in 2023. With the increasing number of percutaneous coronary interventions, changes in the United States FDA policies, and the presence of industry key players. These factors help to the growth of the market. The high prevalence of cardiovascular diseases like coronary artery disease leads to the development of the market in the U.S. and Canada.

The U.S. dominated the market in North America due to its advanced healthcare system and the contribution of the government and key market players. The country is also known for the largest number of fast food chains, which is the main cause of obesity and other health issues. These health issues are leading to various heart and circulatory systems-related disorders.

• In June 2024, Teleflex and their subsidiary Arrow International recalled Arrow FiberOptix and UltraFlex Intra-Aortic Balloon (IAB) Catheter Kits, which were approved by the United States Food and Drug Administration. These kits are used with balloon pumps and are used for patients who suffer from non-cardiac and cardiac surgery and for adult patients’ treatment who suffer from heart failure complications and acute coronary syndrome.

Asia Pacific is poised to grow at a CAGR of 4.71% during the forecast period of 2024-2033. Positive government support and increasing healthcare expenditure contribute to the growth of the angioplasty balloons market. The increasing expenditure is due to the growing heart and circulatory disorders in countries like India due to sedentary lifestyles and unhealthy eating habits.

• In January 2023, according to the report published by the British Heart Foundation, estimated global heart and circulatory disorder deaths in 2021:

Market Overview

The angioplasty balloons market consists of service providers of angioplasty balloons, which are minimally invasive procedures that treat narrowed or blocked arteries. It includes inserting a small balloon into a small vessel and inflating it to treat blockages and enhance blood flow. The benefits of angioplasty balloons include helping to reduce severe angina and also helping people recover from physical activity restricted due to angina. It can help to relieve symptoms of peripheral artery diseases (PAD) and enhance the flow of blood to the legs. Angioplasty balloon is a lifesaving procedure in heart attack that helps to restore the flow of blood to the heart, preventing heart damage and enhancing survival.

Angioplasty Balloons Market Growth Factors

• The benefits of angioplasty balloons include helping to reduce severe angina and also helping people to recover from physical activity restricted due to angina, which helps the market’s growth.
• The angioplasty balloons procedure may recover the symptoms of peripheral artery disease (PAD) and enhance the flow of blood to the legs.
• The angioplasty balloon is a life-saving procedure in heart attack that recovers the flow of blood to the heart, preventing heart damage and enhancing survival, which helps to the growth of the angioplasty balloons market.
• Angioplasty balloon is a safe procedure that is relatively painless and may be effective.

What are the Benefits of AI in the Angioplasty Balloons?

The benefits of artificial intelligence (AI) in angioplasty balloons include providing cardiologists with precise information related to plaque morphology, a stent (tube), balloon dimensions, and post-tube deployment assessment; this leads to total tube expansion and healthier long-term outcomes, which help to the angioplasty balloons market growth. AI in angioplasty balloons helps to improve the hospital’s diagnostic capabilities, enhance procedural accuracy, and help to better patient care. Modern technologies meet life-saving techniques. An Angioplasty balloon is a critical medical treatment for heart health, and it is modified by AI.

• In April 2024, the CE approval and the first European implants of a new ‘BIOMONITOR IV’ insertable cardiac monitor (ICM) were announced by BIOTRONIK. It is the only ICM on the market with PVC and PAC (Premature ventricular and atrial contraction) discrimination capabilities and also industry-leading transmission success and signal quality for highly dependable remote patient management.

Market Scope

Market Dynamics

Driver

Unhealthy lifestyle and rising senior population

The changing unhealthy lifestyle and rising senior population lead to an increase in the prevalence of cardiovascular diseases. It helps to reduce chest pain in coronary artery blockages. This type of pain is known as angina. Angioplasty balloons treat these specific types. In case of a heart attack, angioplasty balloons, an emergency treatment, help to recover or limit the damage right after or during a heart attack. These factors help to grow the angioplasty balloons market.

• According to a report published in 2023 by the National Library of Medicine, peripheral artery disease (PAD) affects over 200 million adults globally, and peripheral artery disease (PAD) incidences increase to 20 percent of people over the age of 70.

Restraint

Risks of angioplasty balloons

The risks of angioplasty balloons include abnormal heart rhythms, a blood clot may form and block a blood vessel in the brain (or stroke), kidney damage specifically in people who suffer from kidney disorders, coronary artery damage, a heart attack can occur at the time of the procedure, accidental perforation caused by incorrect catheter guidewire or catheter, restenosis due to narrowing of the vessel after completing procedure resulting in retreatment that can hamper the angioplasty balloons market growth.

Opportunity

Growth and innovation opportunity

The future growth and innovation opportunities of angioplasty balloons play an important role in the angioplasty balloons market. The use of bioresorbable & biodegradable materials eliminates long-term risks and enhances patient outcomes. Increasing focus on personalized medicine and rising investment in healthcare infrastructure. Evaluating procedural efficacy and safety and standardizing preprocedural planning will be crucial for its success. Enhancing remote monitoring and telemedicine and solutions to improve patient follow-up and care that contribute to the growth of the market.

• In July 2024, a specialty angioplasty balloon medical device company, Summa Therapeutics, expanded their Gen-2 of Summa’s entire Fitness Injectable or multifunctional Angioplasty Catheter Product Line cleared by the Food and Drug Administration for percutaneous transluminal angioplasty (PTA) treatment of PAD (Peripheral Artery Disease) including others, below the knee arteries.

Type Insights

The normal balloons segment dominated the angioplasty balloons market with the largest market share of 55% in 2023. The benefits of normal angioplasty balloons include favorable reimbursement policies, a submission process for approval, supportive government policies, and low costs of devices leading to the growth of the market.

The scoring balloons segment is expected to grow at a CAGR of 5.63% during the forecast period. The scoring/cutting balloons were linked with a lower risk of TLR unaccompanied by an increased risk of clinical adverse events as compared to conventional events. The device has good trackability and flexibility that can make it an ideal device for calcified lesions. The scoring balloons are less noncompliant at high pressure, and their diameter tends to increase.

• In May 2023, the pressure three wire scoring balloons dilation catheter Scoreflex TRIO was developed by a major global medical device manufacturer specializing in interventional devices for PCI (percutaneous coronary intervention) and PTA (percutaneous transluminal angioplasty) procedures, OrbusNeich Medical Group Holdings Limited.

The drug-eluting balloons (DEB) segment is expected to be significantly growing during the forecast period. Drug-eluting balloons (DEB) are coated with medication, and the balloons help prevent artery re-narrowing by stopping cell growth and dividing too much. The benefits of drug-eluting balloons include no acute recoil tackle dissection, abdominal trapping, less drug spillage into the circulation, less requirement of prolonged DAPT mechanical support, accessibility to long segments and complex lesions, leaving no implants, large surface area, and less drug localization in the vessel wall that leads to the growth of the angioplasty balloons market.

Application Insights

The coronary segment has recorded more than 55% of the market share in 2023. In the coronary disorders, angioplasty balloons play an important role. The coronary angioplasty balloon is a procedure to open clogged blood vessels of the heart and treat vessels. It is a small balloon on a narrow tube known as a catheter, which is used to widen a clogged artery and enhance blood flow to help the market’s growth.

• In August 2023, a study of a non-coated angioplasty system was announced by Orchestra BioMed to treat coronary ISR (in-stent restenosis) patients. The study may evaluate the efficacy and safety of the Virtue SAB (Sirolimus AngioInfusion Balloon) System.

The peripheral vascular diseases segment is growing at a CAGR of 4.51% during the forecast period. The angioplasty balloons play an important role in peripheral vascular diseases. The angioplasty balloon can help to reduce severe angina and also help people recover from physical activity restricted due to angina. The angioplasty balloons can recover symptoms of PAD and enhance the flow of blood to the legs helping to the growth of the angioplasty balloons market.

• In January 2024, the first-in-man injectable angioplasty balloon catheter procedures were announced by Summa Therapeutics, LLC. for patients who suffer from below-knee PAD (Peripheral Artery Disease) were performed successfully using Fitness Injectable balloon catheter platform to enhance the effectiveness of periphery angioplasty procedures by reducing contrast needs and equipment.

End-use Insights

The ambulatory surgical centres (ASCs) segment accounted more than 53% of market share in 2023. These ambulatory surgical centers (ASCs) offer patients many benefits over traditional hospital-based surgical procedures, including smaller chances of infectious disease exposure, lower costs, and shorter wait times.

The hospitals segment held the second-largest share of the market in 2023. Hospital benefits include insurance coverage for expenses related to visiting a hospital for health care. The benefits include ambulance services, stays in rehabilitation facilities, emergency room visits, outpatient surgery, intensive care, medical supplies, medical treatments, and room and board.

Angioplasty Balloons Markets Top 14 Companies

• B. Braun Melsungen AG
• ENDOCOR GmbH
• Cook
• BIOTRONIK SE & CO. KG
• Cardinal Health
• Terumo Medical Corporation
• The Spectranetics Corporation
• C.R. Brad, Inc.
• Abbott
• Johnson & Johnson Services, Inc.
• Boston Scientific Corporation
• Medtronic PLC.
• Abbott Laboratories
• MicroPort Scientific Corporation

Recent Developments

• In February 2022, the EMBOGUARD, a next-generation balloon guide catheter used in endovascular procedures, including for patients who suffer from acute ischemic stroke, was launched by an emerging leader in neurovascular care and part of Johnson & Johnson Medical Devices Companies, CERENOVUS.
• In May 2022, the IN. PACT 018 Palitaxel-Coated PTA (Percutaneous Transluminal Angioplasty) balloon catheter, a DEB (drug-eluting balloon), was approved by the United States Food and Drug Administration (FDA) and announced by Medtronic.

Segments Covered in the Report

By Type

• Normal Balloons
• Drug Eluting Balloons
• Cutting Balloons
• Scoring Balloons

By Application

• Periphery
• Coronary

By End-use

• ASCs
• Hospitals
• Cath Labs

By Geography

• North America
• Asia Pacific
• Europe
• Latin America
• Middle East & Africa